Today: 7 February 2026
Subscribe
Browse Category

Cancer Research News 10 December 2025 - 14 January 2026

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

London, Jan 14, 2026, 09:03 GMT — Regular session GSK shares rose in early London trade on Wednesday after Summit Therapeutics said it struck a clinical trial collaboration with the British drugmaker to test a new cancer combination. (MarketScreener) The move lands as investors look for signposts on how much growth GSK can squeeze from its oncology pipeline before it reports full-year results next month. GSK has pencilled in Feb. 4 for its full-year and fourth-quarter update. (GSK) Big drugmakers have been under pressure to refill pipelines as a wave of patent expiries looms for the industry, helping drive a
14 January 2026
······
ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

New York, Jan 13, 2026, 10:45 (EST) — Regular session ImmunityBio, Inc. shares rose about 6% on Tuesday after the company released new lung cancer trial results tied to its immune-boosting drug ANKTIVA. The stock was up 6.4% at $2.76, after touching $2.85 earlier in the session. The move matters because ImmunityBio is trying to widen the case for ANKTIVA beyond its current franchise, and lung cancer is where drug makers chase scale. Traders have been quick to react to any read-through on whether the company can turn trial data into a clearer path for new use cases. In a
13 January 2026
·····
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

New York, January 12, 2026, 13:31 EST — Regular session AbbVie Inc shares slipped Monday following news of a new collaboration with China’s RemeGen to co-develop an experimental solid-tumor drug, as the company ramps up efforts to expand its cancer portfolio via licensing deals. By 1:30 p.m. EST, AbbVie was down 0.6% at $218.81. (Reuters) Investors are focused on how fast AbbVie can transform its oncology pipeline into a real growth driver instead of just another distant promise. The company said the drug could create new combination opportunities with its antibody-drug conjugates, or ADCs — targeted cancer therapies linking an
12 January 2026
·····
Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

ZURICH, Jan 11, 2026, 17:40 CET — The market has closed. Roche Holding shares rose 0.4% on Friday following news that China’s MediLink Therapeutics inked a licensing deal with the Swiss pharma giant for an experimental cancer drug. The stock closed at 340.80 Swiss francs on the SIX Swiss Exchange. (MarketWatch) The deal underscores how big pharma continues to invest heavily in oncology pipelines, despite investor calls for more defined revenue prospects. Antibody-drug conjugates, or ADCs, remain a standout area in cancer R&D — leveraging antibodies to carry lethal agents directly to tumors. Timing is key for Roche. Shares are
11 January 2026
·····
Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

New York, Jan 11, 2026, 10:45 EST — Market closed. Shares of Johnson & Johnson (JNJ.N) dipped 0.7% on Friday to $204.39 following the company’s announcement of a deal with the Trump administration to lower U.S. drug prices. In return, J&J secured exemptions from certain U.S. tariffs. The company said it will offer medicines at discounted rates via TrumpRx.gov and match Medicaid pricing levels seen in other developed countries, though it did not specify which drugs would be involved or the exact discount sizes. The administration made similar deals with nine other pharmaceutical firms in December as part of its
11 January 2026
·····
CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

New York, January 10, 2026, 19:54 EST — The market has closed. CG Oncology Inc (CGON) shares surged nearly 29% on Friday, closing at $54.20 after hitting a session high of $57.36. The stock gained $12.25 during the day on volume of about 7.0 million shares. CG Oncology said it now expects “topline” Phase 3 results—the initial look at main trial endpoints—in the first half of 2026, almost a year earlier than planned. For a clinical-stage biotech, accelerating a key readout can shift investor expectations and company valuations. (Nasdaq) The PIVOT-006 trial, which tests an adjuvant therapy versus surveillance after
11 January 2026
·····
Roche stock in focus after MediLink cancer-drug deal as investors eye Jan. 29 results

Roche stock in focus after MediLink cancer-drug deal as investors eye Jan. 29 results

ZURICH, Jan 10, 2026, 17:45 CET — Market closed Roche Holding (ROG.S) shares edged up on Friday, boosted by news that China’s MediLink Therapeutics secured another licensing deal with the Swiss pharma giant for a cancer drug candidate. Roche participation shares closed 0.4% higher at 340.80 Swiss francs on the SIX Swiss Exchange. (Medilink Therapeutics) Why it matters now: Roche is stepping up dealmaking and licensing efforts to bolster its oncology pipeline, and investors will be eager to see how fast these moves turn into new products. The timing also raises questions about spending discipline, as major R&D investments come
10 January 2026
·····
Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

NEW YORK, Jan 8, 2026, 08:39 EST — Premarket Shares of Immuneering Corp jumped about 24% to $8.33 in premarket trading on Thursday, after the biotech released updated survival data for its lead pancreatic cancer program. The stock last closed at $6.74. The update matters because Immuneering’s valuation hinges on whether atebimetinib can hold up as the company pushes toward a pivotal, late-stage study. For small drug developers without a marketed product, one clinical readout can reset expectations fast. Pancreatic cancer is a tough proving ground. Survival gains are hard to show, and investors tend to discount early-stage results until
8 January 2026
·····
GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

NEW YORK, December 30, 2025, 1:54 PM ET — Regular session Genmab A/S’s U.S.-listed shares (GMAB) fell 3.3% to $31.45 in Tuesday’s regular session. The stock traded between $31.40 and $32.06 after opening at $31.98, with about 1.9 million shares changing hands. The move keeps attention on Genmab’s pipeline as investors reassess which late-stage assets can power growth. Dropping a late-stage program can change a biotech’s outlook quickly because those trials sit closest to potential approvals and revenue. Genmab said on Monday it will discontinue further clinical development of acasunlimab after a portfolio review, citing a more competitive landscape. “After
30 December 2025
·····
JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

NEW YORK, December 29, 2025, 20:26 ET — Market closed Johnson & Johnson (JNJ) shares were last down 0.02% at $207.56 on Monday after the healthcare conglomerate said it completed its $3.05 billion cash acquisition of cancer drug developer Halda Therapeutics. The stock traded between $207.31 and $209.46, and J&J said it will account for the deal as a business combination and expects it to cut adjusted earnings per share by about $0.20, split evenly between the fourth quarter and 2026. JNJ.com The closing matters because it adds another pipeline bet in oncology, where big drugmakers are still hunting for
30 December 2025
·····
Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio Inc. (NYSE: NUVB) has quietly morphed from an obscure penny stock into one of 2025’s wildest oncology stories. As of December 11, 2025, the stock is trading in the high single digits (around $7.8–$8.0), up roughly 200% year‑to‑date, following a string of clinical wins, a first drug approval, and a wave of fresh analyst upgrades. TipRanks+1 The latest jolt came today, when H.C. Wainwright raised its 12‑month price target on NUVB from $10 to $18 while reiterating a Buy / Strong Buy rating – implying well over 100% upside from recent levels. Investing.com+1 Here’s a deep dive into
11 December 2025
·····
Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

As of the session on 10 December 2025, Pfizer Inc. (NYSE: PFE) is trading around $25.5 per share, up modestly on the day and still far below its 2021 peak. The stock now combines a high dividend yield of roughly 6.5–7% with one of the cheapest valuations in big pharma, making it a focal point for income and value investors alike. CoinCentral Today’s move in PFE is being driven by a cluster of fresh catalysts: Below is a detailed, news‑driven look at Pfizer stock today — including the latest news, forecasts and analysis relevant to 10 December 2025. 1. PFE
10 December 2025
····
1 2 3 4 … 6

Stock Market Today

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

7 February 2026
Walmart shares rose 3.3% Friday to $131.18, up 10% since Jan. 30, as the Dow closed above 50,000 for the first time. The retailer’s market value crossed $1 trillion this week. Investors await January inflation data on Feb. 13 and Walmart’s quarterly results on Feb. 19 for signs of continued momentum.
Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

7 February 2026
Caterpillar shares surged 7.1% to $726.20 Friday, driving the Dow above 50,000 for the first time. The move erased recent losses and followed insider selling by Group President Bob De Lange earlier in the week. Deere and CNH Industrial also gained as investors rotated into industrial stocks. Markets await next week’s U.S. jobs and inflation data.
Go toTop